+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

  • PDF Icon

    Report

  • 252 Pages
  • November 2022
  • Region: Global
  • The Business Research Company
  • ID: 5684035
This report describes and explains the adalimumab, infliximab and etanercept biosimilars market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

The global adalimumab, infliximab and etanercept biosimilars market reached a value of nearly $2,757.45 million in 2021, having grown at a compound annual growth rate (CAGR) of 93.90% since 2016. The market is expected to grow from $2,757.45 million in 2021 to $5,591.82 million in 2026 at a rate of 15.20%. The market is then expected to grow at a CAGR of 9.96% from 2026 and reach $8,991.32 million in 2031.

Growth in the historic period resulted from increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs. The market was restrained by the companies gaining market share without a simple price war, low healthcare access and a lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, a rise in healthcare expenditure, aging population and an increase in healthcare access will drive market growth. Factors that could hinder the growth of the adalimumab, infliximab and etanercept biosimilars market in the future include insufficient and outdated health system infrastructure.

The adalimumab, infliximab and etanercept biosimilars market is segmented by product into adalimumab biosimilars, infliximab biosimilars, and Cipleumab. The adalimumab biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021. Going forward, the Cipleumab segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by product, at a CAGR of 17.18% during 2021-2026.

The adalimumab, infliximab and etanercept biosimilars market is also segmented by application into Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and other applications. The other applications market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by application, accounting for 20.1% of the total in 2021. Going forward, the other applications segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by application, at a CAGR of 15.8% during 2021-2026.

The adalimumab, infliximab and etanercept biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, accounting for 87.7% of the total in 2021. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, at a CAGR of 32.2% during 2021-2026.

Western Europe was the largest region in the adalimumab, infliximab and etanercept biosimilars market, accounting for 86.3% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the adalimumab, infliximab and etanercept biosimilars market will be Africa, and, Eastern Europe where growth will be at CAGRs of 110.4% and 56.5% respectively. These will be followed by Middle East, and, South America where the markets are expected to grow at CAGRs of 52.9% and 50.3% respectively.

The global adalimumab, infliximab and etanercept biosimilars market is concentrated, with a small number of large players in the market. The top ten competitors in the market made up to 98.57% of the total market in 2021. Biogen was the largest competitor with 30.14% of the market, followed by Sandoz (Novartis) with23.83 %, Pfizer with 18.04%, Amgen with 7.67%, Celltrion with 4.26%, Samsung Bioepis (Samsung Biologics) with 4.07%, Hetero Drugs Limited with 3.08%, Fresenius Kabi AG with 2.75%, Boehringer Ingelheim with 2.54% and Biocon with2.19 %.

The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by application will arise in the other applications market segment, which will gain $ 601.4 of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel will arise in the hospital pharmacies market segment, which will gain $1,939.2 of global annual sales by 2026. The adalimumab, infliximab and etanercept biosimilars market size will gain the most in the USA at $738.0 million.

Market-trend-based strategies for the adalimumab, infliximab and etanercept biosimilars market include focus on launching new products, focus on mergers and acquisitions, focus on establishing strategic partnerships and focus on increasing investments.

Player-adopted strategies in the adalimumab, infliximab and etanercept biosimilars market include focus on expanding market presence through strategic collaborations and partnerships, focus on meeting the changing needs of health care providers and patients through launching new biosimilar formulations and focus on strengthening business operations through the launch of new products.

To take advantage of the opportunities, the publisher recommends the adalimumab, infliximab and etanercept biosimilars companies to focus on new product launches, expand in emerging markets, increase focus on mergers and acquisitions, offer competitive pricing, continue to participate in events and conferences and focus on fast-growing applications.

Frequently Asked Questions about the Global Adalimumab, Infliximab And Etanercept Biosimilars Market

What is the estimated value of the Global Adalimumab, Infliximab And Etanercept Biosimilars Market?

The Global Adalimumab, Infliximab And Etanercept Biosimilars Market was estimated to be valued at $2757.45 Million in 2021.

What is the growth rate of the Global Adalimumab, Infliximab And Etanercept Biosimilars Market?

The growth rate of the Global Adalimumab, Infliximab And Etanercept Biosimilars Market is 12.5%, with an estimated value of $8991.32 Million by 2031.

What is the forecasted size of the Global Adalimumab, Infliximab And Etanercept Biosimilars Market?

The Global Adalimumab, Infliximab And Etanercept Biosimilars Market is estimated to be worth $8991.32 Million by 2031.

Who are the key companies in the Global Adalimumab, Infliximab And Etanercept Biosimilars Market?

Key companies in the Global Adalimumab, Infliximab And Etanercept Biosimilars Market include Biogen, Novartis (Sandoz), Pfizer and Celltrion.

Table of Contents

1. Adalimumab, Infliximab And Etanercept Biosimilars Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction and Market Characteristics
6.1. General Market Definition
6.2. Summary
6.3. Adalimumab, Infliximab And Etanercept Biosimilars Market Definition and Segmentations
6.4. Market Segmentation By Product
6.4.1. Adalimumab Biosimilars
6.4.2. Infliximab Biosimilars
6.4.3. Etanercept Biosimilars
6.5. Market Segmentation By Application
6.5.1. Crohn’s Disease
6.5.2. Psoriatic Arthritis
6.5.3. Rheumatoid Arthritis
6.5.4. Ulcerative Colitis
6.5.5. Ankylosing Spondylitis
6.5.6. Plaque Psoriasis
6.5.7. Other Applications
6.6. Market Segmentation By Distribution Channel
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Online Pharmacies
7. Major Market Trends
7.1. Robust Competition in the Marketplace
7.2. Growing Mergers And Acquisitions
7.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development
7.4. Large Number Of Strategic Partnerships
7.5. Increasing Investments In Biosimilars Market
8. Global Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, 2016 - 2021, Value ($ Million)
8.2.1. Market Drivers 2016 - 2021
8.2.2. Market Restraints 2016 - 2021
8.3. Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
8.3.1. Market Drivers 2021 - 2026
8.3.2. Market Restraints 2021 - 2026
9. Adalimumab, Infliximab and Etanercept Biosimilars Market, Regional Analysis
9.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
9.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
10. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation
10.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
10.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
10.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distributional Channel, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11. Asia-Pacific Market
11.1. Summary
11.2. Asia Pacific Market Overview
11.2.1. Region Information
11.2.2. Market Information
11.2.3. Background Information
11.2.4. Government Initiatives
11.2.5. Regulations
11.2.6. Regulatory Bodies
11.2.7. Major Associations
11.2.8. Taxes Levied
11.2.9. Corporate Tax Structure
11.2.10. Investments
11.2.11. Major Companies
11.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.5. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.6. Asia Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
11.7. China Market
11.8. Summary
11.9. China Market Overview
11.9.1. Country Information
11.9.2. Market Information
11.9.3. Background Information
11.9.4. Government Initiatives
11.9.5. Regulations
11.9.6. Regulatory Bodies
11.9.7. Major Associations
11.9.8. Taxes Levied
11.9.9. Corporate Tax Structure
11.9.10. Investments
11.9.11. Major Companies
11.10. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.11. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.12. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.13. India Market
11.14. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.15. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.16. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.17. Japan Market
11.18. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.19. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.20. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.21. Australia Market
11.22. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.23. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.24. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.25. Indonesia Market
11.26. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.27. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.28. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
11.29. South Korea Market
11.30. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
11.31. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
11.32. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12. Western Europe Market
12.1. Summary
12.2. Western Europe Market Overview
12.2.1. Region Information
12.2.2. Market Information
12.2.3. Background Information
12.2.4. Government Initiatives
12.2.5. Regulations
12.2.6. Regulatory bodies
12.2.7. Major Associations
12.2.8. Taxes Levied
12.2.9. Corporate Tax Structure
12.2.10. Investments
12.2.11. Major Companies
12.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
12.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
12.5. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12.6. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
12.7. UK Market
12.8. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
12.9. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
12.10. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12.11. Germany Market
12.12. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
12.13. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
12.14. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
12.15. France Market
12.16. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
12.17. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
12.18. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13. Eastern Europe Market
13.1. Summary
13.2. Eastern Europe Market Overview
13.2.1. Region Information
13.2.2. Market Information
13.2.3. Background Information
13.2.4. Government Initiatives
13.2.5. Regulations
13.2.6. Regulatory Bodies
13.2.7. Major Associations
13.2.8. Taxes Levied
13.2.9. Corporate Tax Structure
13.2.10. Investments
13.2.11. Major Companies
13.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.5. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
13.6. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
13.7. Russia Market
13.8. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
13.9. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
13.10. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14. North America Market
14.1. Summary
14.2. North America Market Overview
14.2.1. Region Information
14.2.2. Market Information
14.2.3. Background Information
14.2.4. Government Initiatives
14.2.5. Regulations
14.2.6. Regulatory Bodies
14.2.7. Major Associations
14.2.8. Taxes Levied
14.2.9. Corporate tax structure
14.2.10. Investments
14.2.11. Major Companies
14.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.5. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
14.6. North America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
14.7. USA Market
14.8. Summary
14.9. USA Market Overview
14.9.1. Country Information
14.9.2. Market Information
14.9.3. Background Information
14.9.4. Government Initiatives
14.9.5. Regulations
14.9.6. Regulatory Bodies
14.9.7. Major Associations
14.9.8. Taxes Levied
14.9.9. Corporate Tax Structure
14.9.10. Investments
14.9.11. Major Companies
14.10. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
14.11. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
14.12. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15. South America Market
15.1. Summary
15.2. South America Market Overview
15.2.1. Region Information
15.2.2. Market Information
15.2.3. Background Information
15.2.4. Government Initiatives
15.2.5. Regulations
15.2.6. Regulatory Bodies
15.2.7. Major Associations
15.2.8. Taxes Levied
15.2.9. Corporate Tax Structure
15.2.10. Investments
15.2.11. Major Companies
15.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
15.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
15.5. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
15.6. South America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis
15.7. Brazil Market
15.8. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
15.9. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
15.10. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
16. Middle East Market
16.1. Summary
16.2. Middle East Market Overview
16.2.1. Region Information
16.2.2. Market Information
16.2.3. Background Information
16.2.4. Government Initiatives
16.2.5. Regulations
16.2.6. Regulatory Bodies
16.2.7. Major Associations
16.2.8. Taxes Levied
16.2.9. Corporate Tax Structure
16.2.10. Investments
16.2.11. Major Companies
16.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
16.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
16.5. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
17. Africa Market
17.1. Summary
17.2. Africa Market Overview
17.2.1. Region Information
17.2.2. Market Information
17.2.3. Background Information
17.2.4. Government Initiatives
17.2.5. Regulations
17.2.6. Regulatory Bodies
17.2.7. Major Associations
17.2.8. Taxes Levied
17.2.9. Corporate Tax Structure
17.2.10. Investments
17.2.11. Major Companies
17.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 - 2021, Value ($ Million)
17.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 - 2026, 2031F Value ($ Million)
17.5. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 - 2021, 2026F, 2031F, Value ($ Million)
18. Competitive Landscape And Company Profiles
19. Company Profiles
19.1. Biogen
19.1.1. Company Overview
19.1.2. Products And Services.
19.1.3. Business Strategy
19.1.4. Financial Overview
19.2. Novartis AG (Sandoz)
19.2.1. Company Overview
19.2.2. Products And Services.
19.2.3. Business Strategy
19.2.4. Financial Overview
19.3. Pfizer Inc.
19.3.1. Company Overview
19.3.2. Products And Services
19.3.3. Business Strategy
19.3.4. Financial Overview
19.4. Amgen Inc
19.4.1. Company Overview
19.4.2. Products And Services.
19.4.3. Business Strategy
19.4.4. Financial Overview
19.5. Celltrion
19.5.1. Company Overview
19.5.2. Products And Services
19.5.3. Business Strategy
19.5.4. Financial Overview
20. Pipeline Analysis
21. Key Mergers And Acquisitions In The Market
21.1. Fresenius Kabi Acquired mAbxience
21.2. Biocon Biologics to Acquire Viatris Biosimilars Business
21.3. Celltrion Acquired Assets Of Takeda Pharmaceuticals
21.4. Amgen Acquired Japanese JV with Astellas
21.5. True North Acquired Stake In Biocon Biologics Ltd.
21.6. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India
21.7. Ligand Pharmaceuticals Acquired Pfenex
21.8. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.
21.9. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital
21.10. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech
21.11. Biocon Merged With Sandoz
22. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Opportunities And Strategies
22.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 - Countries Offering Most New Opportunities
22.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 - Segments Offering Most New Opportunities
22.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market In 2026 - Growth Strategies
22.3.1. Market Trend Based Strategies
22.3.2. Competitor Strategies
23. Adalimumab, Infliximab and Etanercept Biosimilars Market, Conclusions And Recommendations
23.1. Conclusions
23.2. Recommendations
23.2.1. Product
23.2.2. Place
23.2.3. Price
23.2.4. Promotion
23.2.5. People
24. Appendix
24.1. Market Data Sources
24.2. Research Methodology
24.3. Currencies
24.4. About the Publisher
24.5. Copyright and Disclaimer

Executive Summary

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031 from the publisher provides the strategists; marketers and senior management with the critical information they need to assess the global adalimumab, infliximab and etanercept biosimilars market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Description:

Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The adalimumab, infliximab and etanercept biosimilars market global report from the publisher answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider adalimumab, infliximab and etanercept biosimilars market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about adalimumab, infliximab and etanercept biosimilars market
  • Key Trends - Highlights the major trends shaping the global adalimumab, infliximab and etanercept biosimilars market. This section also highlights likely future developments in the market
  • Global Market Size and Growth - Global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods
  • Regional Analysis - Historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values and growth and market share comparison by region
  • Market Segmentation - Contains the market values (2016-2031) and analysis for for segment by product, by application, and by distribution channel in the market
  • Regional Market Size and Growth - Regional market size (2021), historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players
  • Pipeline Analysis - Briefs on the pipeline analysis of adalimumab, infliximab and etanercept biosimilars from the major players in the market
  • Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years
  • Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets
  • Conclusions And Recommendations - Includes recommendations for adalimumab, infliximab and etanercept biosimilars providers in terms of product/service offerings, geographic expansion, marketing strategies and target groups
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report

Scope

Markets Covered:

  • 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
  • 2) By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion

Countries: Australia; China; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; adalimumab, infliximab and etanercept biosimilars indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Biogen
  • Novartis (Sandoz)
  • Pfizer
  • Amgen
  • Celltrion

Methodology

Loading
LOADING...